A federal expert panel has recommended an expansion of RSV vaccinations for adults aged 50 to 59 with specific health risks and endorsed a new combination meningococcal vaccine. Additionally, a recommendation for a new chikungunya vaccine aimed at travelers aged 12 and above was made. While such recommendations typically lead to CDC approvals, current uncertainty surrounds the decision-making process due to the acting CDC director's recusal and potential involvement from the Health Secretary, particularly given his controversial stance on vaccinations.
The Advisory Committee on Immunization Practices unanimously recommended that adults, particularly those aged 50 to 59 with certain health risks, receive RSV vaccinations.
A new combination meningococcal shot was endorsed for adults, designed to protect against several strains of bacteria, especially amidst past outbreaks on campuses.
A second chikungunya vaccine option was recommended for Americans aged 12 and older, aimed at providing protection for travelers from this mosquito-borne illness.
The decision-making for the CDC's recommendations may be influenced by acting director Susan Monarez's recusal and the potential involvement of Health Secretary Robert F. Kennedy Jr.
Collection
[
|
...
]